dr. debu tripathy on 10 versus 5 years of adjuvant tamoxifen
Published 11 years ago • 262 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:20
dr. tripathy on 10 versus 5 years of aromatase inhibitors
-
0:50
debu tripathy on hormone therapy compliance in patients with breast cancer
-
1:09
dr. debu tripathy on molecular predictors of outcome in breast cancer
-
1:19
debu tripathy on hormonal therapy for breast cancer
-
1:54
debu tripathy on genetic risks for breast cancer
-
3:12
first in history- us drug, dostarlimab cures every patient of cancer. is cancer cure finally here?
-
1:46
5 most curable cancers l cancers that are curable l cancer
-
5:36
who's science in 5: older adults and covid-19 vaccines - 14 october 2022
-
1:25
dr. debu tripathy reviews the phase iii confirm trial
-
1:22
dr. debu tripathy gives an overview of targeted therapies for breast cancer
-
2:13
dr. tripathy on frontline endocrine therapies in hr breast cancer
-
0:54
dr. tripathy on the treatment of patients with metastatic breast cancer
-
2:00
dr. tripathy on personalized therapy options in metastatic breast cancer
-
0:38
dr. tripathy on completing new assays after recurrence
-
1:47
dr. tripathy on combination strategies with cdk4/6 inhibitors in breast cancer
-
1:55
debu tripathy on using breast cancer tumor dna to make treatment decisions
-
2:39
dr. tripathy on integrative oncology
-
1:21
dr. tripathy on combination strategies with cdk4/6 inhibitors in hr breast cancer
-
2:34
sabcs: debu tripathy discusses hormonal therapy advances in breast cancer
-
2:55
dr. tripathy on the development of palbociclib in breast cancer
-
2:24
dr. tripathy on genomically guided therapy in breast cancer
-
1:23
dr. tripathy discusses breast cancer prevention